{
    "clinical_study": {
        "@rank": "43810", 
        "arm_group": {
            "arm_group_label": "EPO906", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will examine whether the investigational drug EPO906, given by intravenous\n      infusion (IV directly into the vein), is effective in shrinking tumors and preventing the\n      growth of cells that cause breast cancer."
        }, 
        "brief_title": "EPO906 Therapy in Patients With Advanced Breast Cancer", 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The following patients may be eligible for this study:\n\n          -  Histologically or cytologically documented evidence of disease with at least one\n             measurable lesion;\n\n          -  Life expectancy of greater than three (3) months;\n\n          -  Patients who have had only one prior therapy for metastatic disease;\n\n          -  Patients who have received prior treatment with hormonal agents or who have had prior\n             treatment regimens of radiotherapy in addition to one or no previous chemotherapy\n             regimens are eligible;\n\n          -  Patients who have had no prior therapy for metastatic disease, but who have received\n             a taxane and an anthracycline (single or combination therapy) as adjuvant treatment,\n             are eligible.  For patients who have had previous radiation therapy to the target\n             lesion(s), the lesion(s) must since have demonstrated progression.\n\n        Exclusion Criteria:\n\n        The following patients are not eligible for this study:\n\n          -  Bone-only disease;\n\n          -  Symptomatic pleural effusions;\n\n          -  Symptomatic CNS metastases or leptomeningeal involvement;\n\n          -  Any peripheral neuropathy or unresolved diarrhea greater than Grade 1;\n\n          -  Severe cardiac insufficiency;\n\n          -  Patients taking Coumadin or other warfarin-containing agents with the exception of\n             low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports;\n\n          -  History of another malignancy within 5 years prior to study entry except curatively\n             treated non-melanoma ckin cancer or cervical cancer in situ;\n\n          -  Active or suspected acute or chronic uncontrolled infection including abcesses or\n             fistulae;\n\n          -  HIV+ patients;\n\n          -  Pregnant or lactating females;\n\n          -  Patients who have had radiation, chemotherapy, or hormonal therapy within the last\n             four (4) weeks excluding palliative radiotherapy to isolated peripheral bone\n             metastases not being used as markers for efficacy;\n\n          -  Patients taking Herceptin less than three (3) weeks prior to study start."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035126", 
            "org_study_id": "CEPO906A2205"
        }, 
        "intervention": {
            "arm_group_label": "EPO906", 
            "intervention_name": "epothilone b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epothilone B", 
                "Epothilones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "breast", 
            "cancer", 
            "tumor", 
            "tumour", 
            "intravenous", 
            "epothilone", 
            "taxane", 
            "anthracycline"
        ], 
        "lastchanged_date": "September 23, 2011", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth Hitchcock Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08901"
                    }, 
                    "name": "Cancer Institute of New Jersey (CINJ)"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "until disease progression, death or date of last follow-up"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "date of death or last date patient was known to be alive"
            }, 
            {
                "measure": "Duration of overall response", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks as clinically needed"
            }, 
            {
                "measure": "Safety of study drug", 
                "safety_issue": "Yes", 
                "time_frame": "weekly for the first 8 weeks, then every other week"
            }, 
            {
                "measure": "pharmacokinectics of study drug", 
                "safety_issue": "No", 
                "time_frame": "every 8 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2011"
    }, 
    "geocoordinates": {
        "Cancer Institute of New Jersey (CINJ)": "40.486 -74.452", 
        "Dartmouth Hitchcock Medical Center": "43.642 -72.252"
    }
}